Aspirin, salicylates and cancer

Peter C. Elwood; Alison M. Gallagher; Garry G. Duthie; Luis A. J. Mur; Gareth Morgan

doi:10.1016/S0140-6736(09)60243-9

Aspirin, salicylates and cancer

Peter C. Elwood, Alison M. Gallagher, Garry G. Duthie, Luis A. J. Mur, Gareth Morgan

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

256 Citations (Scopus)

Abstract

Evidence from a wide range of sources suggests that individuals taking aspirin and related non-steroidal anti-inflammatory drugs have reduced risk of large bowel cancer. Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants. However, opportunistic trials of aspirin, designed to test vascular protection, provide some evidence of a reduction in cancer, but only after at least 10 years. We summarise evidence for the potential benefit of aspirin and natural salicylates in cancer prevention. Possible mechanisms of action and directions for further work are discussed, and implications for clinical practice are considered.

Original language	English
Pages (from-to)	1301-1309
Number of pages	9
Journal	The Lancet
Volume	373
Issue number	9671
DOIs	https://doi.org/10.1016/S0140-6736(09)60243-9
Publication status	Published - 11 Apr 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(09)60243-9

http://hdl.handle.net/2160/4515

Permanent link

Persistent link

Cite this

@article{8d423358327a46ad8f41fb46f3efc8a2,

title = "Aspirin, salicylates and cancer",

abstract = "Evidence from a wide range of sources suggests that individuals taking aspirin and related non-steroidal anti-inflammatory drugs have reduced risk of large bowel cancer. Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants. However, opportunistic trials of aspirin, designed to test vascular protection, provide some evidence of a reduction in cancer, but only after at least 10 years. We summarise evidence for the potential benefit of aspirin and natural salicylates in cancer prevention. Possible mechanisms of action and directions for further work are discussed, and implications for clinical practice are considered.",

author = "Elwood, {Peter C.} and Gallagher, {Alison M.} and Duthie, {Garry G.} and Mur, {Luis A. J.} and Gareth Morgan",

note = "Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A. J., Morgan, G. (2009). Aspirin, salicylates and cancer. The Lancet, 373, (9671), 1301-1309. IMPF: 30.76 RONO: 00 ",

year = "2009",

month = apr,

day = "11",

doi = "10.1016/S0140-6736(09)60243-9",

language = "English",

volume = "373",

pages = "1301--1309",

journal = "The Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9671",

}

TY - JOUR

T1 - Aspirin, salicylates and cancer

AU - Elwood, Peter C.

AU - Gallagher, Alison M.

AU - Duthie, Garry G.

AU - Mur, Luis A. J.

AU - Morgan, Gareth

N1 - Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A. J., Morgan, G. (2009). Aspirin, salicylates and cancer. The Lancet, 373, (9671), 1301-1309. IMPF: 30.76 RONO: 00

PY - 2009/4/11

Y1 - 2009/4/11

N2 - Evidence from a wide range of sources suggests that individuals taking aspirin and related non-steroidal anti-inflammatory drugs have reduced risk of large bowel cancer. Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants. However, opportunistic trials of aspirin, designed to test vascular protection, provide some evidence of a reduction in cancer, but only after at least 10 years. We summarise evidence for the potential benefit of aspirin and natural salicylates in cancer prevention. Possible mechanisms of action and directions for further work are discussed, and implications for clinical practice are considered.

AB - Evidence from a wide range of sources suggests that individuals taking aspirin and related non-steroidal anti-inflammatory drugs have reduced risk of large bowel cancer. Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants. However, opportunistic trials of aspirin, designed to test vascular protection, provide some evidence of a reduction in cancer, but only after at least 10 years. We summarise evidence for the potential benefit of aspirin and natural salicylates in cancer prevention. Possible mechanisms of action and directions for further work are discussed, and implications for clinical practice are considered.

U2 - 10.1016/S0140-6736(09)60243-9

DO - 10.1016/S0140-6736(09)60243-9

M3 - Article

SN - 1474-547X

VL - 373

SP - 1301

EP - 1309

JO - The Lancet

JF - The Lancet

IS - 9671

ER -

Aspirin, salicylates and cancer

Abstract

UN SDGs

Access to Document

Permanent link

Fingerprint

Cite this